Tin tức & Cập nhật
Lọc theo Chuyên ngành:

3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
At the second interim analysis of part 1 of the phase III RUBY study, updated duration of response (DoR) findings suggest that women with primary advanced or recurrent endometrial cancer who have achieved a response with the combination regimen comprising dostarlimab and carboplatin-paclitaxel (CP) have substantially improved DoR.
3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
17 Apr 2025
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
15 Apr 2025
TB vax primer augments BCG-induced immune response in bladder cancer patients
Initial results of the phase I RUTIVAC-1 study show the potential of two doses of a tuberculosis (TB) vaccine given after surgery but before standard BCG* treatment to boost immunity and reduce the odds of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).